Croitoru Marina E, Cleary Sean P, Berk Terri, Di Nicola Nando, Kopolovic Ilana, Bapat Bharati, Gallinger Steven
Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
J Surg Oncol. 2007 May 1;95(6):499-506. doi: 10.1002/jso.20724.
MYH is a member of the DNA base excision repair (BER) pathway and mutations of this gene predispose to the development of colorectal neoplasia in an autosomal recessive transmission pattern. Our objective was to determine the significance of MYH mutations in a series of Canadian patients with multiple adenomas.
We screened for germline MYH mutations (by dHPLCO) in 20 clinic-based multiple adenoma patients who were adenomatous polyposis coli (APC) mutation-negative. Suspected mutations were confirmed by sequence analysis.
Six of 20 (30%) patients carried pathogenic biallelic MYH mutations, 1 Y165C homozygote and 5 compound heterozygotes of other sequence variants. We identified three novel variants, Q377X, 1314delA, and P281L, which are likely pathogenic. Twenty-nine relatives of the Y90X/1103delC compound heterozygous carrier were also screened for germline MYH mutations, and 1 homozygous and 14 heterozygous carriers were identified.
Among patients with multiple adenomas, biallelic MYH mutations account for approximately 30% of APC mutation negative cases and two thirds of these carry mutations other than the "common" Y165C and G382D variants. Clinical screening algorithms which focus only on the Y165C and G382D alleles are inadequate since additional pathogenic mutations may be identified by screening the entire gene.
MYH是DNA碱基切除修复(BER)途径的成员,该基因的突变以常染色体隐性遗传模式使患结直肠肿瘤的风险增加。我们的目的是确定一系列加拿大多发性腺瘤患者中MYH突变的意义。
我们对20例临床诊断为多发性腺瘤且腺瘤性息肉病(APC)基因无突变的患者进行了种系MYH突变筛查(采用dHPLCO法)。疑似突变通过序列分析进行确认。
20例患者中有6例(30%)携带致病性双等位基因MYH突变,其中1例为Y165C纯合子,5例为其他序列变异的复合杂合子。我们鉴定出三个新的变异体,Q377X、1314delA和P281L,它们可能具有致病性。我们还对Y90X/1103delC复合杂合子携带者的29名亲属进行了种系MYH突变筛查,鉴定出1名纯合子携带者和14名杂合子携带者。
在多发性腺瘤患者中,双等位基因MYH突变约占APC基因无突变病例的30%,其中三分之二携带的突变不是“常见的”Y165C和G382D变异体。仅关注Y165C和G382D等位基因的临床筛查算法是不够的,因为通过对整个基因进行筛查可能会发现其他致病性突变。